New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
09:28 EDTGERN, CTICCell Therapeutics to benefit from Geron troubles, says Roth Capital
After Geron's (GERN) telomerase inhibitor for myelofibrosis and other settings was put on full clinical hold due to potential liver injury, Roth Capital thinks that the competitive positioning of Cell Therapeutics' (CTIC) myelofibrosis treatment, Pacritinib, has improved. The firm keeps a Buy rating on Cell Therapeutics.
News For CTIC;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:54 EDTCTICCTI BioPharma files to sell 9M shares of common stock for holders
16:40 EDTCTICCTI BioPharma files $200M mixed securities shelf
Subscribe for More Information
10:50 EDTGERNGeron November volatility at low end of two-year range as shares trend higher
Geron December call option implied volatility is at 86, January is at 88, March is at 78; compared to its 26-week average of 106 according to Track Data, suggesting decreasing price risk.
November 19, 2014
07:09 EDTCTICJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
11:06 EDTGERN, CTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 14, 2014
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use